A phase 1 clinical trial with M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in an expansion cohort of 35 patients with recurrent GBM, progressed after radiotherapy plus temozolomide. Here, TGFB1 is linked to glioblastoma.